Precision cancer therapy has a funny contradiction at its core: sometimes the best way to control a drug is not to deliver the finished drug at all, but to smuggle in the parts and let the cell assemble the contraption only when you flip the lights on.
That, in a civilized nutshell, is the idea behind a new paper on something called a photo-click PROTAC. If that phrase sounds like chemistry won a bet with science fiction, you are not entirely wrong. The authors describe a system that keeps two inactive molecular pieces apart until light exposure uncages one of them and triggers a bioorthogonal "click" reaction inside the cell, generating active PROTACs on site. In triple-negative breast cancer cells, those freshly assembled degraders then went after not one cancer-linked protein, but two: BRD4 and PARP1 [1].
A Tiny Hit Squad, Built on Location
A standard PROTAC is already a clever beast. It is a two-headed molecule: one end grabs a target protein, the other recruits an E3 ligase such as cereblon, and the cell's disposal machinery does the rest. Rather than merely blocking a protein like a sulky valet parking your car, a PROTAC tags the whole thing for removal. Very satisfying. Slightly vindictive. Quite modern [2-4].
The catch is that PROTACs can be large, awkward molecules. Medicinal chemists have spent years trying to persuade them to travel through the body politely, stay soluble, enter cells, and avoid collateral damage. This paper attacks that problem sideways. Instead of delivering the full degrader, the researchers delivered pieces: a photocaged dibenzosilacycloheptyne attached to either JQ1 or olaparib, and an azide-tagged pomalidomide piece to recruit CRBN. Shine light, uncage the reactive partner, click the pieces together inside the cell, and now you have active PROTACs where and when you want them [1].
It is rather like sending flat-pack furniture into a bad neighborhood and only handing over the Allen key when the intended recipient is already indoors.
Why Two Targets Are Better Than One
The authors focused on triple-negative breast cancer, a subtype with an unfortunate habit of ignoring some of the easiest hormonal handles oncologists like to grab. BRD4 helps regulate transcriptional programs that tumors enjoy abusing, while PARP1 is central to DNA repair. Knocking down both at once is a sensible bit of strategic impatience: one target meddles with gene expression, the other with repair, and together they may leave cancer cells with fewer escape routes.
In MDA-MB-231 cells, the light-triggered system generated dual PROTACs that degraded BRD4 and PARP1 simultaneously. The paper reports antiproliferative activity 25-fold stronger than the unirradiated inhibitors and 2.4-fold stronger than the corresponding PROTAC combination delivered without this light-triggered in-cell assembly trick [1].
That is the sort of result that makes researchers sit up straighter and medicinal chemists briefly forgive the universe for inventing pharmacokinetics.
The Real Magic Trick Is Control
The deeper appeal here is not merely potency. It is control.
Cancer drugs are forever negotiating the same old problem: how do you hit the bad actors without turning the rest of the body into a regrettable side quest? Conditional PROTAC strategies have become a lively area precisely because the field wants more spatial and temporal control - in plain English, more say over where degradation happens and when it starts [5]. Light-activated systems are especially attractive because they let you localize activation with unusual precision, at least in principle.
And yes, one must immediately add the usual professorly throat-clearing. Light does not travel through human tissue with unlimited enthusiasm. Triple-negative breast cancer in a dish is not the same as a tumor in an actual patient with blood vessels, stromal cells, immune cells, and all the other meddlesome citizens of the tumor microenvironment. Cancer biology, as usual, refuses to be simple out of sheer personality.
Still, the concept is elegant. It borrows from bioorthogonal chemistry, the branch of chemistry devoted to reactions that can occur in living systems without barging rudely into native biochemistry [6]. In effect, the authors use a reaction the cell does not normally perform, at a moment the experimenter chooses, to build a degrader exactly where it is needed. That is not just clever chemistry. It is a new way of thinking about drug selectivity.
Why This Matters Beyond One Paper
Targeted protein degradation has moved from intriguing idea to clinical reality. On May 1, 2026, the FDA approved vepdegestrant, a heterobifunctional protein degrader, for ESR1-mutated metastatic breast cancer. So this is no longer a parlor game for chemists with expensive hobbies. The field has entered the clinic.
What papers like this one add is the next layer of ambition. Not just "can we degrade the protein?" but "can we degrade it only in the tumor, only at the chosen time, maybe even only after combining several local signals?" If that works, the upside is obvious: less off-target toxicity, smarter combinations, and a better chance of using degraders against proteins and contexts that would otherwise be too risky.
After half a century of watching cancer therapeutics alternate between brilliance and overconfidence, I have learned to distrust anything that sounds too tidy. We were once assured interferon would sort everything out. It did not. But this study has the right kind of untidiness. It solves a real problem with a fresh idea, and it does so in a way that could scale into a broader toolkit.
Not bad for a molecule that only becomes itself after the lights come on.
References
-
Pang J, Li S, Zhang Y, Jia Q, Long Y-Q. Photo-click Proteolysis-Targeting Chimeras Enable Intracellular Generation of PROTACs for Precise Dual Protein Degradation. Angew Chem Int Ed. 2026. DOI: https://doi.org/10.1002/anie.202518897
-
Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181-200. DOI: https://doi.org/10.1038/s41573-021-00371-6
-
Tsai JM, Nowak RP, Ebert BL, Fischer ES, et al. Targeted protein degradation: from mechanisms to clinic. Nat Rev Mol Cell Biol. 2024;25:740-757. DOI: https://doi.org/10.1038/s41580-024-00729-9
-
Zhong G, Chang X, Xie W, Zhou X, et al. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Ther. 2024;9:308. DOI: https://doi.org/10.1038/s41392-024-02004-x PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11539257/
-
Yim J, Park J, Kim G, Lee HH, Chung JS, Jo A, Koh M, Park J. Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation. ChemMedChem. 2024;19:e202400326. DOI: https://doi.org/10.1002/cmdc.202400326 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11581424/
-
Yang C, Tripathi R, Wang B. Click chemistry in the development of PROTACs. RSC Chem Biol. 2024;5:189-197. DOI: https://doi.org/10.1039/D3CB00199G PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC10915971/
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.